NANOBIOTIX PARTNERS WITH WEILL CORNELL
MEDICINE ON PRE-CLINICAL STUDIES TO EVALUATE THE
IMPACT OF NBTXR3 ON cGAS-STING PATHWAY IN MAMMARY
CANCERS
Paris, France and Cambridge, Massachusetts,
USA, May 3, 2018 - NANOBIOTIX (Euronext: NANO - ISIN:
FR0011341205), a late clinical-stage nanomedicine company
pioneering new approaches to the treatment of cancer, announced
today that it is launching a research collaboration with Weill
Cornell Medicine to begin nonclinical studies of NBTXR3's mechanism
of action. NBTXR3 is a first-in-class product designed to destroy,
when activated by radiotherapy, tumors and metastasis through
physical cell death and to induce immunogenic cell death leading to
specific activation of the immune system.
The research collaboration between Weill Cornell
Medicine, based in New York City, and Nanobiotix will be conducted
over the course of one year, with the goal of continuing the
exploration of the role of NBTXR3 in Immuno-Oncology.
The main objective of this collaboration is to
study the impact of NBTXR3 activated by radiotherapy on the
cGAS-STING pathway using different in vitro and in vivo murine
models (mammary). Along with immunogenic cell death, the cGAS-STING
pathway has emerged as the key component of the anti-tumor immune
response. Data generated from this collaboration could support
current evidence indicating that NBTXR3 activated by radiotherapy
can increase the anti-tumor immune response, compared with
radiotherapy alone, and transform an irradiated tumor into an
efficient in situ vaccine.
Dr. Sandra Demaria, M.D., Professor of Radiation
Oncology and Chief of the Division of Experimental Radiotherapy in
the Department of Radiation Oncology at Weill Cornell Medicine, and
Principal Investigator for the study, said: "We have learned that
radiotherapy has the potential to convert a tumor into an in-situ
vaccine, and enhance systemic tumor responses to immunotherapy. But
there is room for improvement: NBTXR3 nanoparticles enhance the
pro-immunogenic effects of radiotherapy, and we want to understand
how they work. This knowledge will further the development of this
innovative approach for the treatment of cancer patients who are
resistant to immune checkpoint inhibitors."
The Company received the FDA's approval to
launch a clinical study of NBTXR3 activated by radiotherapy in
combination with anti-PD1 antibody in lung, and head and neck
cancer patients (head and neck squamous cell carcinoma and nonsmall
cell lung cancer). This trial that shall start in Q2 2018, aims to
expand the potential of NBTXR3, including using it to treat
recurrent or metastatic disease.
NBTXR3 positioning in IOMany IO
combination strategies focus on 'priming' the tumor, which is now
becoming a prerequisite of turning a "cold" tumor into a "hot"
tumor.
Compared to other modalities that could be used
for priming the tumor, NBTXR3 could have a number of advantages:
the physical and universal mode of action that could be used widely
across oncology, a one-time local injection and good fit within
existing medical practice already used as a basis for cancer
treatment, as well as a very good chronic safety profile and
well-established manufacturing process.
Published preclinical and clinical data indicate
that NBTXR3 could play a key role in oncology and could become a
backbone in immuno-oncology.
Nanobiotix's immuno-oncology combination program
opens the door to new developments, potential new indications, and
important value creation opportunities.
-ends-
About NBTXR3NBTXR3 is a first-in-class
product designed to destroy, when activated by radiotherapy, tumors
and metastasis through physical cell death and to immunogenic cell
death leading to specific activation of the immune system.
NBTXR3 has a high degree of biocompatibility,
requires one single administration before the whole radiotherapy
treatment and has the ability to fit into current worldwide
standards of radiation care.
NBTXR3 is being evaluated in head and neck
cancer (locally advanced squamous cell carcinoma of the oral cavity
or oropharynx), and the trial targets frail and elderly patients
who have advanced cancer with very limited therapeutic options. The
Phase I/II trial has already delivered very promising results
regarding the local control of the tumors and a potential
metastatic control through in situ vaccination.
Nanobiotix is running an Immuno-Oncology program
with NBTXR3 that includes several studies. In the U.S., the Company
received the FDA's approval to launch a clinical study of NBTXR3
activated by radiotherapy in combination with anti-PD1 antibodies
in lung, and head and neck cancer patients (head and neck squamous
cell carcinoma and non-small cell lung cancer). This trial aims to
expand the potential of NBTXR3, including using it to treat
recurrent or metastatic disease.
The first market authorization process (CE
Marking) is ongoing in Europe in the soft tissue sarcoma
indication.
The other ongoing studies are treating patients
with liver cancers (hepatocellular carcinoma and liver metastasis),
locally advanced or unresectable rectal cancer in combination with
chemotherapy, head and neck cancer in combination with concurrent
chemotherapy, and prostate adenocarcinoma.
***
About NANOBIOTIX:
www.nanobiotix.com Incorporated in 2003, Nanobiotix is a leading,
late clinical-stage nanomedicine company pioneering new approaches
to significantly change patient outcomes by bringing nanophysics to
the heart of the cell.
The Nanobiotix philosophy is one rooted in
designing pioneer physical based approaches to bring highly
effective and generalized solutions to address high unmet medical
needs and challenges.
The Company's first-in-class, proprietary lead
technology, NanoXray, aims to expand radiotherapy benefits for
millions of cancer patients. Furthermore, the Company's
Immuno-Oncology program has the potential to bring a new dimension
to cancer immunotherapies.
Nanobiotix is listed on the regulated market of
Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg:
NANO: FP). The Company's Headquarters are based in Paris, France,
with a U.S. affiliate in Cambridge, MA, and european affiliates in
Spain and Germany.
Contact
Nanobiotix |
Sarah GaubertDirector, Communication & Public
Affairs+33 (0)1 40 26 07 55sarah.gaubert@nanobiotix.com
/contact@nanobiotix.com |
Noël Kurdi Director, Investor
Relations +1 (646) 241-4400 noel.kurdi@nanobiotix.com /
investors@nanobiotix.com |
Media relations |
France -
Springbok ConsultantsMarina Rosoff+33 (0)6 71 58 00
34marina@springbok.fr |
|
United States -
RooneyPartners Marion Janic +1 (212)
223-4017mjanic@rooneyco.com |
|
Disclaimer This press release contains certain
forward-looking statements concerning Nanobiotix and its business.
Such forward-looking statements are based on assumptions that
Nanobiotix considers to be reasonable. However, there can be no
assurance that the estimates contained in such forward-looking
statements will be verified, which estimates are subject to
numerous risks including the risks set forth in the reference
document of Nanobiotix filed with the French Financial Markets
Authority (Autorité des Marchés Financiers) under number D.17-0470
on April 28, 2017 as well as in its 2017 annual financial report
filed with the French Financial Markets Authority on March 29, 2018
(a copy of which is available on www.nanobiotix.com) and to the
development of economic conditions, financial markets and the
markets in which Nanobiotix operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Nanobiotix or not currently considered
material by Nanobiotix. The occurrence of all or part of such risks
could cause actual results, financial conditions, performance or
achievements of Nanobiotix to be materially different from such
forward-looking statements. This press release and the information
that it contains do not constitute an offer to sell or subscribe
for, or a solicitation of an offer to purchase or subscribe for,
Nanobiotix shares in any country. At the moment NBTXR3 does not
bear a CE mark and is not permitted to be placed on the market or
put into service until NBTXR3 has obtained a CE mark.
Nanobiotix (EU:NANO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Nanobiotix (EU:NANO)
Historical Stock Chart
From Aug 2023 to Aug 2024